Dasabuvir

Phase 3Small molecule

AbbVie

Dasabuvir is one of 161 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

160

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

Hepatitis CActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Chronic Hepatitis C Virus InfectionActive, not recruiting

Hepatitis C Virus InfectionActive, not recruiting

Chronic HepatitisPreclinical

Active, not recruiting

Hepatitis CPhase 2

Active, not recruiting

Chronic Kidney DiseasePhase 3

Active, not recruiting

Chronic Hepatitis C Virus InfectionPhase 3

Active, not recruiting

Hepatitis C Virus InfectionPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

Dasabuvir

AbbVie

Phase 3

7 2

PEG-Intron

Merck & Co.

Preclinical

43 3

Sovaldi

Gilead

Preclinical

34 4

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

199 5

Incivek

Vertex Pharmaceuticals

Preclinical

10 6

Intron a

Sanofi

Preclinical

7 7

Roferon-a

Roche

Preclinical

3 8

Medrol

Pfizer

Preclinical

1 9

SOF/VEL

Gilead

Preclinical

4 10

Keyhole-Limpet Hemocyanin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Hepatitis7 trials

Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium

Completed· AbbVie logo

AbbVie··NCT02581163·314 enrolled

A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection

Completed· AbbVie logo

AbbVie·Phase 3·NCT02216422·36 enrolled

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C

Completed· AbbVie logo

AbbVie··NCT02725866·216 enrolled

Show 4 more trials

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis

Completed· AbbVie logo

AbbVie·Phase 3·NCT02219503·60 enrolled

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C

Completed· AbbVie logo

AbbVie··NCT02803138·256 enrolled

The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland

Completed· AbbVie logo

AbbVie··NCT02582671·101 enrolled

Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada

Completed· AbbVie logo

AbbVie··NCT02581189·565 enrolled

Hepatitis C4 trials

Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults

Completed· AbbVie logo

AbbVie·Phase 2·NCT02493855·46 enrolled

Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P

Completed·KKirby Institute·Phase 3·NCT02634008·83 enrolled

Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults

Completed· AbbVie logo

AbbVie·Phase 3·NCT02476617·25 enrolled

Show 1 more trial

A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults

Completed· AbbVie logo

AbbVie·Phase 3·NCT02582632·166 enrolled

Hepatitis C Virus Infection2 trials

A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects

Completed· AbbVie logo

AbbVie·Phase 2/3·NCT02486406·64 enrolled

Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT02194998·46 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions

Completed·VValme University Hospital··NCT02333292·1,128 enrolled

Chronic Kidney Disease1 trial

Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease

Completed· AbbVie logo

AbbVie·Phase 3·NCT02207088·68 enrolled

3 more indications

Treatment1 trial

Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment

Active, not recruiting·NNova Scotia Health Authority·Phase 4·NCT02460133·44 enrolled

Chronic Hepatitis C Virus Infection1 trial

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis

Completed· AbbVie logo

AbbVie·Phase 3·NCT02219477·36 enrolled

Antiviral Drug1 trial

Efficacy Study to Evaluate the Effect of New Antiviral Drugs on HCV Infection.

Unknown status·UUniversity of Modena and Reggio Emilia·Phase 4·NCT02950870·75 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Dasabuvir. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dasabuvir compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dasabuvir. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AbbVie

Dasabuvir

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Hepatitis7 trials

Hepatitis C4 trials

Hepatitis C Virus Infection2 trials

Efficacy and Safety1 trial

Chronic Kidney Disease1 trial

Treatment1 trial

Chronic Hepatitis C Virus Infection1 trial

Antiviral Drug1 trial

References

Drug Info

Quick Facts

Related News